{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-002673","form_type":"8-K","ticker":"BEAM","cik":"0001745999","company_name":"Beam Therapeutics Inc.","filed_at":"2024-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.372629+00:00","generated_at":"2026-06-07T02:24:55.279966+00:00","sec_items":["2.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Beam dosed first SCD patient, submitted CTA for AATD, cash $1.2B into 2027","bullets":["First patient dosed in BEACON Phase 1/2 trial of BEAM-101 for sickle cell disease; initial data expected H2 2024.","CTA submitted for BEAM-302 in alpha-1 antitrypsin deficiency; trial initiation planned H1 2024.","IND for BEAM-301 in glycogen storage disease 1a on track for H1 2024.","Estimated cash, cash equivalents and marketable securities of $1.2B as of Dec 31, 2023, funding operations into 2027.","BEAM-201 CAR-T trial enrollment ongoing; initial clinical dataset expected H2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-002673","json":"https://secwatch.observer/filing/0000950170-24-002673.json","markdown":"https://secwatch.observer/filing/0000950170-24-002673.md","text":"https://secwatch.observer/filing/0000950170-24-002673.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1745999/000095017024002673/0000950170-24-002673-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1745999/000095017024002673/beam-20240108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T02:24:55.279966+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}